Lorlatinib and its Impurities

Lorlatinib is approved in the US and in Europe for the second- or third-line treatment of ALK-positive metastatic non-small-cell lung cancer (NSCLC). Reference standards of Lorlatinib API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.